Aeras Highlights Commitment to Eradicating the World's Leading Infectious Disease Killer at the 5th Global Forum on Tuberculosis
NEW DELHI, Feb. 19, 2018 /PRNewswire-USNewswire/ -- Aeras, a nonprofit organization dedicated to developing vaccines against tuberculosis (TB), will highlight the progress being made in TB vaccine research at the 5(th) Global Forum on TB Vaccines in New Delhi, India, February 20-23, 2018. Presentations will include new data from Aeras's advancing portfolio of TB vaccines, including data from four clinical-stage candidates.
Ann Ginsberg, MD, PhD, Chief Medical Officer at Aeras and a member of the organizing committee for the 5(th) Global Forum on TB Vaccines, said: "We and our partners will share a range of new data at the 5(th) Global Forum on TB Vaccines, highlighting the scientific progress being made to develop potential new vaccines against TB, the world's leading cause of death from an infectious disease."
Over the past decade, more than a dozen new TB vaccine candidates have been tested in human clinical trials around the world. Serving as a critical translational bridge from the bench to the field, Aeras has sponsored and conducted over 55 clinical and epidemiological studies in 15 different countries. It has worked with partners to develop new approaches to R&D and new tools, such as the Controlled Human Infection Model. In addition, Aeras has contributed to preclinical research efforts by creating improved animal models of disease to facilitate and enhance initial screening for promising TB vaccine candidates.
First Data from Innovative Prevention-of-Infection Phase 2 Clinical Trial
Results will be presented for the first time from the Phase 2 prevention-of-infection clinical trial evaluating H4:IC31, a subunit vaccine candidate, and revaccination with Bacille Calmette-Guérin (BCG), the world's only commercially available TB vaccine. The study was conducted to evaluate the safety and immunogenicity of the vaccine regimens, as well as their ability to prevent initial and sustained TB infections among healthy adolescents in the Western Cape Province of South Africa.
Additional Clinical-Stage TB Vaccine Portfolio Data
Data will also be presented on other clinical-stage TB vaccines, including:
-- Data from a Phase 1/2a clinical trial evaluating the safety and
immunogenicity of various dose regimens of H56:IC31 in HIV-negative
adults with and without latent TB infection.
-- Follow-up data from a Phase 1 clinical study, evaluating the ability of
the GLA-SE adjuvant to improve the magnitude and quality of immune
response to the ID93 vaccine. This study was the first in which the ID93
vaccine was tested in humans.
-- Data from a Phase 1b trial evaluating different doses of the ID93+GLA-SE
vaccine for use in TB endemic countries.
-- Learnings associated with the impact of implementing an effective
community engagement strategy on retention rates in a Phase 2b
prevention-of-disease study for the M72 vaccine in South Africa, Zambia
and Kenya.
Note to Editors
A full list of abstracts associated with research conducted and/or funded by Aeras to be presented at the 5(th) Global Forum on TB Vaccines is as follows:
(Note: All 5(th) Global Forum presentations and posters will take place within the Taj Diplomatic Enclave Hotel (formerly Taj Palace), located at 2 Sardar Patel Marg, Diplomatic Enclave, New Delhi. The times provided are in India Standard Time.)
Abstract # Title Presentation Details
---------- ----- --------------------
PS-
05 Enriching cohorts for smaller, quicker, more Plenary Session 1: Increasing
efficient TB vaccine efficacy trials Probability of Success and
Maximizing Impact
Time: 14:00 - 16:00, February 20
Location: Shahjehan
--- -------------------
PD-
08 Demonstration of a correlation between the in Poster Discussion 1: Basic Vaccine
vitro direct mycobacterial growth inhibition Concepts and Correlates of
assay (MGIA) and protection from in vivo Protective Immunity
mycobacterial challenge Time 16:15 - 17:45, February 20
Location: Roshanara
--- -------------------
PD-
24 The ESAT-6 free IGRA, a companion diagnostic Poster Discussion 2: Diagnostics
for ESAT-6 based TB vaccines and Epidemiology
Time: 16:15 - 17:45, February 20
Location: Sheesh Mahal
--- ----------------------
PD-
28 Optimization and interpretation of serial
QuantiFERON testing to measure acquisition of
M. tuberculosis infection
--- -------------------------
PA-
10 Synthetic Polysaccharide Conjugate Vaccines Poster Viewing: Novel Vaccine
Expressing Mycobacterium tuberculosis Antigens Concepts, Chemistry,
Induce High-titer Antibody Responses in Mice, Manufacturing and Controls
Guinea Pigs, and Rabbits Time: 16:15 - 17:45, February 20
Location: Mumtaz Mahal
--- ----------------------
PA-
16 Comparison of pellicle and liquid grown BCG
reference strains in standard BCG batch release
assays and protection studies
--- -----------------------------
PS-
06 Prevention of infection with Mycobacterium Plenary Session 2: Clinical
tuberculosis by H4:IC31 vaccination or BCG Development of New TB Vaccines
revaccination n healthy adolescents: results of a Time: 9:00 - 11:00, February 21
randomized controlled trial Location: Shahjehan
--- --------------------------- -------------------
PS-
10 A critical juncture in tuberculosis vaccine clinical
development: overview of progress
--- ---------------------------------
PS-
07 Community engagement and Good Participatory
Practice Guidelines for TB vaccine research and
development
--- -----------
OA-
09 Clinical development of ID93+GLA-SE as a Breakout Presentation 2: Clinical
prophylactic or therapeutic vaccine for Research
tuberculosis Time: 11:30 - 13:30, February 21
Location: Jejangir
--- ------------------
PS-
11 The route of BCG vaccination determines Plenary Session 3: Novel
immunity and protection against Approaches to TB Vaccine
Mycobacterium tuberculosis infection in non- Research & Development
human primates Time: 14:00 - 16:00, February 21
Location: Shahjehan
--- -------------------
PS-
12 Vaccination following mycobacterial exposure
--- --------------------------------------------
PD-
15 T cell immunity in the lung and protection Poster Discussion 3: Preclinical
following aerosol, intravenous, or intradermal Research
administration of BCG in nonhuman primates Time: 16:30 - 18:00, February 21
Location: Roshanara
--- -------------------
PD-
14 Animal dose response curve predicts lower
optimal tuberculosis vaccine dose in humans:
The use of vaccine Immunostimulation/
Immunodynamic modelling methods to inform
vaccine dose decision-making
--- ----------------------------
PD-
34 Immunogenicity of AERAS-404 or BCG Poster Discussion 4: Clinical
revaccination in a prevention of established M. Research and Community
tuberculosis infection efficacy trial Engagement
Time: 16:30 - 18:00, February 21
Location: Sheesh Mahal
--- ----------------------
PD-
38 Safety and immunogenicity of H56:IC31 in HIV-
negative adults with and without latent
tuberculosis (TB) infection
--- ---------------------------
PD-
37 The Toll-like Receptor 4 agonist adjuvant, GLA-
SE, improves magnitude and quality of immune
responses elicited by the ID93 tuberculosis vaccine
--- ---------------------------------------------------
PD-
36 Dose definition of the novel TB vaccine
ID93+GLA-SE for TB endemic countries
--- ------------------------------------
PD-
39 Impact of implementing an effective community
engagement strategy on retention rates in a
Phase 2b Prevention of Disease TB vaccine trial
in South Africa, Zambia, and Kenya
--- ----------------------------------
OA-
16 Immunogenicity and efficacy evaluation of Breakout Session 3: Novel Vaccine
prime-boost vaccine regimens with ChAd3-4Ag Concepts and Preclinical Research
+/- MVA5Ag in rhesus macaques Time: 11:30 - 13:00, February 22
Location: Shahjehan
--- -------------------
OA-
21 Evaluating immune correlates of risk of Breakout Session 4: Biomarkers,
Mycobacteria tuberculosis infection in humans Correlates and Epidemiology
Time: 11:30 - 13:00, February 22
Location: Jehangir
--- ------------------
About Aeras
Aeras is a nonprofit organization advancing the development of new tuberculosis vaccines for the world in partnership with other biotech, pharmaceutical and academic organizations. Aeras is primarily funded by The Bill & Melinda Gates Foundation, the UK Department for International Development (DFID), and other parties committed to ending the TB epidemic. Aeras also receives support from the U.S. government and through partnerships and collaborations with universities and pharmaceutical companies around the world. Aeras is headquartered in Rockville, Maryland (USA), with a clinical development and operations office in Cape Town, South Africa. For more information, please visit www.aeras.org.
Aeras is a lead organizing partner of the 5(th) Global Forum on TB Vaccines.
For more information, contact:
Jennie Willson at jwillson@aeras.org or +1 301-547-2840
View original content:http://www.prnewswire.com/news-releases/aeras-highlights-commitment-to-eradicating-the-worlds-leading-infectious-disease-killer-at-the-5th-global-forum-on-tuberculosis-300600421.html
SOURCE Aeras
